- CSR Summary Not yet available
- NCT03090100
- Primary Citation
- Data Specification Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaImmune System DiseasesEnrollment1048% Female32.5%% White93.4%
Product ClassmAB anti-IL12 and anti-IL23Sponsor Protocol NumberCNTO1959PSO3009Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)45.8
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0356 : Combining clinical trials with external data: applications in the YODA database
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2022-4894 : Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of RCTs